Rodman&Renshaw：重申annovis bio(ANVS.US)评级，由买入调整至买入评级,目标价由67.00美元调整至67.00美元。
Annovis Bio(ANVS.US)公司简介：Annovis Bio Inc是一家临床阶段的制药公司，专注于开发和商业化治疗帕金森氏症和阿尔茨海默氏病和其他神经退行性疾病的药物。公司管道产品有ANVS-401、ANVS-405、ANVS-301。
English
Back
- Markets
- Features
- News
- Community
- Learn
- Help Center
- About
- Offers & Rewards
- English
- 繁體中文
- 简体中文
- Dark
- Light
Rodman & Renshaw：重申Annovis Bio(ANVS.US)评级
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.